Back

Ipilimumab, pembrolizumab and nivolumab exerts different cardiac and vascular toxicity through DAMPs fibronectin-EDA, S100/calgranulin, galectine-3 and associated NLRP3 inflammasome-chemokine pathway

23 May 2022 (08:30 - 19:45)
Organised by:
Congress Presentation Part of: Heart Failure ePosters - focus on Comorbidities and special population Cardio-Oncology HFA Premium Access Heart Failure 2022

About the speaker

Photo
Doctor Vincenzo Quagliariello

National Cancer Institute G.Pascale Foundation IRCCS, Naples (Italy)

35 More presentations in this session

Presentation thumbnail
A brazilian perspective about the impact of covid 19 on hospitalizations for venous tromboembolism and pulmonary embolism
Mr E. Biscarde (BR)
Abstract Slides
Presentation thumbnail
Diastolic disfunction in precapillary pulmonary hypertension - looking left to see right
Doctor P. Alves da Silva (Lisbon, PT)
Abstract Slides
Presentation thumbnail
Pulmonary hypertension in connective tissue diseases with overt of features of venous/capillaries involvement: clinical implications and prognostic impact of this phenotype.
Doctor J. Grade Santos (Almada, PT)
Abstract Slides
Presentation thumbnail
Risk stratification in pulmonary arterial hypertension: do our patients benefit from a 4-strata model?
Doctor J. Grade Santos (Almada, PT)
Abstract Slides
Presentation thumbnail
Comparison of risk scores calculators in patients newly diagnosed with pulmonary arterial hypertension.
Doctor J. Grade Santos (Almada, PT)
Abstract Slides

Access the full session

Session thumbnail
Heart Failure ePosters - focus on Comorbidities and special population

The Event

Event poster

Heart Failure 2022

23 May 2022 08:30 CET

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources